REGENXBIO Inc. et al v. Sarepta Therapeutics, Inc., et al.

  1. January 05, 2024

    Sarepta Avoids IP Claims As Judge Finds UPenn Patent Invalid

    A Delaware judge found a gene therapy patent at the center of an infringement suit against Sarepta, brought by the University of Pennsylvania, was ineligible for patent protection because the claims cover a combination of two recombinant DNA sequences that are already naturally occurring.

  2. January 04, 2022

    No 'Safe Harbor' For Gene Therapy Found In Hatch-Waxman

    A Delaware federal judge told Massachusetts biotechnology company Sarepta on Tuesday that it could not use the "safe harbor" provisions of the Hatch-Waxman Act to protect a gene therapy it is developing with Roche to treat muscular dystrophy from a patent infringement lawsuit by the University of Pennsylvania.

  3. December 16, 2021

    IP Forecast: Feds To Spar With Gilead Over CEO's Testimony

    Gilead Sciences will ask a Delaware federal judge next week to block the federal government from deposing the pharmaceutical company's CEO in a high-profile patent case over allegations Gilead made billions by selling HIV medications using research funded by taxpayers. Here's a look at that case — plus all the other major intellectual property matters on deck in the coming week.